CA2942571C - Conjugates of an il-15 moiety and a polymer - Google Patents

Conjugates of an il-15 moiety and a polymer Download PDF

Info

Publication number
CA2942571C
CA2942571C CA2942571A CA2942571A CA2942571C CA 2942571 C CA2942571 C CA 2942571C CA 2942571 A CA2942571 A CA 2942571A CA 2942571 A CA2942571 A CA 2942571A CA 2942571 C CA2942571 C CA 2942571C
Authority
CA
Canada
Prior art keywords
moiety
conjugate
polymer
ch2ch2
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2942571A
Other languages
English (en)
French (fr)
Other versions
CA2942571A1 (en
Inventor
Xiaofeng Liu
Peter Benedict Kirk
Thomas Chang
Deborah H. Charych
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CA2942571A1 publication Critical patent/CA2942571A1/en
Application granted granted Critical
Publication of CA2942571C publication Critical patent/CA2942571C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2942571A 2014-04-03 2015-04-01 Conjugates of an il-15 moiety and a polymer Active CA2942571C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03
US61/974,914 2014-04-03
PCT/US2015/023871 WO2015153753A2 (en) 2014-04-03 2015-04-01 Conjugates of an il-15 moiety and a polymer

Publications (2)

Publication Number Publication Date
CA2942571A1 CA2942571A1 (en) 2015-10-08
CA2942571C true CA2942571C (en) 2023-09-19

Family

ID=54241432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2942571A Active CA2942571C (en) 2014-04-03 2015-04-01 Conjugates of an il-15 moiety and a polymer

Country Status (12)

Country Link
US (1) US20170035898A1 (enExample)
EP (2) EP3139947B8 (enExample)
JP (2) JP6728055B2 (enExample)
KR (1) KR102432169B1 (enExample)
CN (1) CN106456716A (enExample)
AU (3) AU2015240806B2 (enExample)
CA (1) CA2942571C (enExample)
ES (1) ES2876433T3 (enExample)
IL (1) IL248169A0 (enExample)
MA (1) MA39711A (enExample)
MX (2) MX388865B (enExample)
WO (1) WO2015153753A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
AU2015333827A1 (en) 2014-10-14 2017-04-20 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
ES2941234T3 (es) 2014-10-22 2023-05-19 Armo Biosciences Inc Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
JP7407511B2 (ja) 2015-10-08 2024-01-04 ネクター セラピューティクス ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用
JP2019503348A (ja) * 2015-12-21 2019-02-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
EP3468581A1 (en) 2016-06-13 2019-04-17 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN119700941A (zh) * 2017-05-15 2025-03-28 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
CN112004547A (zh) * 2018-02-26 2020-11-27 新索思股份有限公司 Il-15缀合物及其用途
MX2021005485A (es) * 2018-11-09 2021-06-18 Nektar Therapeutics Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
US20220193253A1 (en) * 2019-04-26 2022-06-23 Prolynx Llc Slow-release cytokine conjugates
US11248025B2 (en) 2019-06-03 2022-02-15 Medikine, Inc. IL-2alpha receptor subunit binding compounds
US12344648B2 (en) * 2019-08-23 2025-07-01 Synthrox, Inc. IL-15 conjugates and uses thereof
CN117355337A (zh) * 2021-03-29 2024-01-05 奥迪曼药业科技有限公司 蛋白-大分子缀合物及其使用方法
BR112023027305A2 (pt) 2021-06-23 2024-03-12 Cytune Pharma Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
WO2023288226A2 (en) * 2021-07-12 2023-01-19 Nektar Therapeutics Polymer engineered forms of interferon-gamma and methods of use
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2025101551A1 (en) * 2023-11-06 2025-05-15 Regents Of The University Of Minnesota Prostate-specific membrane antigen (psma)-binding peptides and method of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
ATE196315T1 (de) 1994-04-06 2000-09-15 Immunex Corp Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
DE60329627D1 (de) * 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
CA2509939C (en) 2003-01-06 2013-05-21 Nektar Therapeutics Al, Corporation Thiol-selective water-soluble polymer derivatives
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
TW200619227A (en) * 2004-08-11 2006-06-16 Hoffmann La Roche Mutant interleukin-15-containing compositions and suppression of an immune response
AU2005335217A1 (en) 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of B cell proliferation by IL-15
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
PL2431741T3 (pl) * 2008-10-21 2014-01-31 Baxalta Inc Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
EP3505186B1 (en) * 2010-07-30 2022-01-12 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
HRP20210642T1 (hr) * 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer

Also Published As

Publication number Publication date
JP2020114875A (ja) 2020-07-30
AU2021258008A1 (en) 2021-11-25
JP6728055B2 (ja) 2020-07-22
EP3139947B1 (en) 2021-05-26
WO2015153753A3 (en) 2015-11-26
IL248169A0 (en) 2016-11-30
MA39711A (fr) 2015-10-08
AU2019283778A1 (en) 2020-01-16
CA2942571A1 (en) 2015-10-08
KR102432169B1 (ko) 2022-08-11
KR20170005793A (ko) 2017-01-16
MX2021015492A (es) 2022-02-22
EP3139947A2 (en) 2017-03-15
ES2876433T3 (es) 2021-11-12
MX388865B (es) 2025-03-20
AU2015240806B2 (en) 2019-09-19
AU2015240806A1 (en) 2016-10-13
EP3139947B8 (en) 2021-06-30
MX2016012908A (es) 2017-01-11
EP3139947A4 (en) 2018-01-17
JP2017511322A (ja) 2017-04-20
WO2015153753A2 (en) 2015-10-08
US20170035898A1 (en) 2017-02-09
EP3919071A1 (en) 2021-12-08
CN106456716A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
CA2942571C (en) Conjugates of an il-15 moiety and a polymer
AU2022268401B2 (en) Conjugates of an IL-2 moiety and a polymer
AU2016228555B2 (en) Conjugates of an IL-7 moiety and a polymer
BRPI0614257A2 (pt) conjugados de uma porção de g-csf e um polìmero
WO2013020079A2 (en) Conjugates of an il-11 moiety and a polymer
HK1235666B (en) Conjugates of il-15 and branched polyethylene glycol
HK1235666A1 (en) Conjugates of il-15 and branched polyethylene glycol
HK40053166A (en) Conjugates of an il-2 moiety and a polymer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200318

EEER Examination request

Effective date: 20200318

EEER Examination request

Effective date: 20200318

EEER Examination request

Effective date: 20200318

EEER Examination request

Effective date: 20200318

EEER Examination request

Effective date: 20200318

EEER Examination request

Effective date: 20200318

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317